Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Data on adverse drug reactions reported by researchers at Baylor College of Medicine, College of Medicine
May 4th, 2008
"Donepezil is licensed for the treatment of mild-to-moderate Alzheimer's disease (AD) at doses of 5-10 mg/day and has recently been approved in the US for severe AD. Multiple studies have suggested that donepezil 10 mg/day provides additional cognitive and functional benefits over the 5 mg/ day dose," investigators in the United States report. "Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD. To evaluate the safety and tolerability of donepezil at doses of 15 and 20 mg/day. A 24-week, randomized, double-blind, placebo-controlled, pilot study conducted at two investigational sites in the US. Enrolled patients...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-04)
|
